基于2020年版《中华人民共和国药典》含黄精成方制剂分析

Analysis of Prescription Preparations Containing Polygonatum Sibiricum in the 2020 Edition of the Chinese Pharmacopoeia

目的:分析2020年版《中华人民共和国药典》(以下简称《中国药典》)中含黄精成方制剂的收载情况,为其综合开发研究提供参考依据。方法:查阅2020年版《中国药典》一部中含黄精的成方制剂,对含黄精成方制剂的名称、处方组成、黄精炮制品选材、常用配伍药、剂型、功效等情况进行数据统计,并归类分析。结果:2020年版《中国药典》一部收载的含黄精的成方制剂有31个(通过若干药味组成、功能主治一致,仅剂型存在差异的制剂则合并为某方,合并后统计含黄精处方为21个),处方组成的药味数少则有4味,多则有22味;选材主要为黄精(57.14%);常用配伍药有黄芪(炙黄芪)(57.14%)、地黄(熟地黄)(52.38%)、枸杞(42.86%)等;剂型有片剂(35.48%)、胶囊剂(25.81%)、颗粒剂(22.58%)等;功效以滋补肝肾(85.71%)和补气(57.14%)为主。结论:2020年版《中国药典》一部收载的含黄精的成方制剂较少,黄精选材名称不够规范,剂型分布少,制法简单,无黄精有效成分作为含量检测指标,应加强黄精在复方制剂中的综合开发研究。

Objective:To analyze the collection status of prescription preparations Containing Polygonatum sibiricum in 2020 edition of the Chinese Pharmacopoeia,and to provide a reference for its comprehensive development research.Methods:Consult the prescription preparations containing Polygonatum sibiricum in the 2020 edition of the Chinese Pharmacopoeia(Part 1),conduct data statistics on the name of the prescription preparations,prescription composition,material selection of Polygonatum sibiricum processed products,commonly used compatibility drugs,dosage forms,efficacy,etc.,and classification analysis.Results:There are 31 prescription preparations containing Polygonatum sibiricum contained in the 2020 edition of the Chinese Pharmacopoeia(preparations with the same medicinal flavor and the same functions and indications,and preparations with only differences in dosage form are combined into a certain prescription,the total number of prescriptions containing Polygonatum sibiricum was 21 after merging).The ingredients of set prescription preparations as few as 4 and as many as 22;the main material selected is Polygonatum sibiricum(57.14%);the commonly used compatibility drugs include Astragalus(roasted Astragalus)(57.14%),Rehmannia glutinosa(prepared rehmannia root)(52.38%),wolfberry(42.86%),etc,dosage forms include tablets(35.48%),capsules(25.81%),granules(22.58%),etc,the main functions are nourishing the liver and kidneys(85.71%)and replenishing Qi(57.14%).Conclusion:There are not many prescription preparations containing Polygonatum sibiricum in the 2020 edition of Chinese Pharmacopoeia,material selection of Polygonatum sibiricum processed products is not standardized enough,with less dosage forms and simple preparation methods.No active ingredients of Polygonatum sibiricum used as content detection indicators,The comprehensive development research of Polygonatum sibiricum in compound preparations should be strengthened.